Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)
A clinical study to determine the safety, efficacy and mechanism of action of sitagliptin alone and in combination with pioglitazone, in patients with type 2 diabetes mellitus who have inadequate glycemic (blood sugar) control.
- Trial name
- NCT00511108
- Testing
- Comparator: sitagliptin phosphate, Comparator: pioglitazone
- Volunteers
- 211 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition…
- Trial name
- NCT04531462
- Testing
- Empagliflozin
- Where
- 18 sites in Japan
- Volunteers
- 129 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.
- Trial name
- NCT00757588
- Testing
- Saxagliptin, 5 mg + insulin
- Where
- 80 sites in United States, Canada and 8 more
- Volunteers
- 455 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight…
- Trial name
- NCT01029886
- Testing
- exenatide once weekly, liraglutide
- Where
- 108 sites in Argentina, Australia and 19 more
- Volunteers
- 912 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any…
- Trial name
- NCT00643851
- Testing
- Dapagliflozin, Metformin XR
- Where
- 99 sites in United States, Mexico and 5 more
- Volunteers
- 994 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
This is a study to evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in combination with sitagliptin in the treatment of participants with Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on…
- Trial name
- NCT02226003
- Testing
- Ertugliflozin, Sitagliptin, Glimepiride
- Volunteers
- 291 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
The objective of the randomised part of the study is to investigate the efficacy and safety of BI 1356 plus metformin compared to BI 1356 or metformin alone given for 24 weeks to drug naive or previously treated (4 weeks…
- Trial name
- NCT00798161
- Testing
- BI 1356, BI 1356 + metformin, Metformin
- Where
- 138 sites in Canada, Croatia and 12 more
- Volunteers
- 857 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
Efficacy of BI 1356 compared to placebo in patients for whom metformin therapy is inappropriate (intolerability, contraindication).
- Trial name
- NCT00740051
- Testing
- Linagliptin, Glimepiride
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 227 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
The purpose of this study is to assess the safety and efficacy of omarigliptin compared to placebo in participants with inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT01755156
- Testing
- Omarigliptin, Glimepiride, Insulin glargine
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-102 at daily doses of 400 and 600 mg vs. placebo and Actos® 30 mg (up-titrated to 45 mg after 8 weeks) when administered for up to 24 weeks in…
- Trial name
- NCT00814372
- Testing
- MBX-102, Actos, Metformin
- Where
- 26 sites in United States, India
- Volunteers
- 242 people
- Sponsor
- Gilead Sciences
Primary Hypercholesterolemia
DNV001 Injection in Patients With Hypercholesterolemia
This is a Phase II clinical study to evaluate the effectiveness and safety of different doses of DNV001 injection in patients with primary hypercholesterolemia or mixed dyslipidemia who have not achieved adequate control of…
- Trial name
- DNV001 (NCT07391722)
- Testing
- DNV001 Injection
- Volunteers
- 120 people
- Sponsor
- Hangzhou Dinovate Biotech Co., Ltd
Diabetes Mellitus, Type 2
Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus.
- Trial name
- NCT00767000
- Testing
- MK-0941, Lantus, Metformin
- Volunteers
- 813 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
Efficacy and safety of BI 1356 compared to placebo in patients with type 2 diabetes who have insufficient glycaemic control despite treatment with a sulfonylurea drug.
- Trial name
- NCT00819091
- Testing
- BI 1356
- Where
- 45 sites in United States, Argentina and 5 more
- Volunteers
- 245 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
Phase 3 study to assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients
- Trial name
- NCT05226897
- Testing
- YYC405-T, Metformin≥1000mg, Dapagliflozin 10mg
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus
The purpose of this study is to compare the reduction in hemoglobin A1C (A1C) for participants taking saxagliptin in combination with metformin immediate release (IR) versus metformin IR alone.
- Trial name
- NCT00885378
- Testing
- Saxagliptin plus metformin IR
- Where
- 41 sites in United States, Germany and 2 more
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).
- Trial name
- NCT00094770
- Testing
- sitagliptin (MK0431), Comparator: glipizide
- Volunteers
- 1,172 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.
- Trial name
- NCT00885352
- Testing
- Sitagliptin, Pioglitazone, Metformin
- Volunteers
- 313 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Japanese P III vs Voglibose and Placebo
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (BI 1356) (5 mg or 10 mg / once daily) compared to placebo given for 12 weeks and voglibose for 26 weeks as mono therapy in…
- Trial name
- NCT00654381
- Testing
- BI 1356, voglibose
- Where
- 47 sites in Japan
- Volunteers
- 561 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin…
- Trial name
- NCT00666458
- Testing
- saxagliptin, sitagliptin
- Where
- 87 sites in Argentina, Belgium and 7 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca